Overview

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
0
Participant gender:
All
Summary
Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
Brimonidine Tartrate
Brinzolamide
Latanoprost
Ophthalmic Solutions
Tetrahydrozoline
Criteria
Inclusion Criteria:

- Glaucoma or ocular hypertension in both eyes

- Currently being treated with latanoprost 0.005% QD

- IOP greater than or equal to 18mm Hg on latanoprost 0.005%

- Best-corrected VA of 20/200 or better in each eye

- Visual field within 6 months of study entry

Exclusion Criteria:

- Secondary glaucoma

- Active intraocular inflammation or macular edema

- Intraocular surgery or laser surgery within the past 3 months